Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A research melanocortin agonist associated with pigmentation, appetite, and sexual-function history. Those themes are not an approved tanning product. PT-141 is a different cyclic peptide.
Scenesse (afamelanotide) is a different molecule. Melanotan II is not that implant and not bremelanotide.
Non-selective melanocortin agonism is the pigmentation and central-pathway story. Nausea and blood pressure are the safety themes stored here.
Development of bremelanotide split a more selective molecule off this chemistry. Melanotan II remains the non-selective research peptide.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Tanning protocol · unverified
Community tanning and libido schedules are widespread and Grade F. The protocol library treats melanotan II as a high-concern research agonist, not a cosmetic.
From the Catalyst protocol research library. Community schedules there are Grade F and are not a dose.